Medical Cannabis Industry in Europe

Introduction: Europe's Medical Cannabis Industry Scales Into a Regulated Pharmaceutical Market

The Europe Medical Cannabis Industry has moved decisively from a patchwork of national pilot programmes into a credentialed pharmaceutical market with prescriptions, import quotas, reimbursement pathways and EU-GMP supply chains. According to IMARC Group, the market reached USD 3,060.0 Million in 2025 and is projected to reach USD 13,161.29 Million by 2034, expanding at a CAGR of 17.60% (2026–2034). The policy trigger was German. The Medical Cannabis Act (MedCanG), in force from 1 April 2024, removed medical cannabis from the Narcotics Act (BtMG) and replaced case-by-case narcotic exemptions with ordinary physician prescriptions dispensed through community pharmacies the largest single regulatory break in European cannabis policy to date.

The demand response has been measurable rather than speculative. Germany's Federal Institute for Drugs and Medical Devices (BfArM) reported medical cannabis imports of 201.1 tonnes in 2025, up from roughly 72.9 tonnes in 2024, after the authority raised the national maximum quantity for medical and scientific purposes to approximately 192.5 tonnes in October 2025. In the United Kingdom, Home Office data released under Freedom of Information in April 2026 showed imports of dried cannabis flower for medicinal use rising to 30,062 kilograms in 2025 from 14,992 kilograms in 2024 a second consecutive doubling. Supply-side investment is following the demand: EU-GMP certified cultivation in Portugal, Denmark, Spain and North Macedonia, German domestic production under BfArM tender, and a wave of pharmacy, clinic and distribution acquisitions led by North American operators.

At the segmentation level, Indica holds the largest share by species, cannabidiol (CBD)-led products account for over half of the market by derivative, and cancer-related applications form the largest therapeutic use case as clinicians manage pain, nausea and appetite loss. Oral solutions and capsules dominate by route of administration with a 55.2% share, reflecting Europe's pharmaceutical rather than retail orientation. Regionally the market remains concentrated in Germany and the United Kingdom, with Portugal and Denmark functioning as the cultivation and export base and France, Italy, Spain and Poland forming the next demand tier. The defining theme of 2026 is pharmaceuticalisation: private telemedicine clinics, EU-GMP processing and specialist pharmacy distribution now decide who captures value as commodity flower prices fall.

This blog examines the Europe Medical Cannabis Industry's size and segments, recent announcements, trends shaping 2026, geographic hotspots, competitive landscape, policy environment, forecast through 2034, and the opportunities available to manufacturers, investors, technology providers and distributors.

Key Takeaways

• The Europe Medical Cannabis Industry was valued at USD 3,060.0 Million in 2025 and is forecast to reach USD 13,161.29 Million by 2034, growing at a CAGR of 17.60% (2026–2034).
• Oral solutions and capsules lead by route of administration with a 37% market share, CBD-led products account for over half the market by derivative, Indica is the largest species and cancer is the largest single application.
• Germany is the largest national market and the world's biggest legal import destination: imports reached 201.1 tonnes in 2025, up from about 72.9 tonnes in 2024, with Canada supplying 93,006 kilograms (46%) and Portugal 55,164 kilograms.
• The United Kingdom is Europe's fastest-growing second market, importing 30,062 kilograms of dried flower in 2025 against 14,992 kilograms in 2024, with patient numbers projected to pass 140,000 during 2026 and roughly 80% of prescriptions issued through fewer than a dozen telemedicine platforms.
• In September 2026, Red White & Bloom Brands closed a controlling interest in HEAL Europe Holdings Corp., taking an indirect 50.1% of Germany's Grünhorn Gruppe AG and about 61.3% of UK-based Zerenia Clinics and Leva HEAL, supported by a CAD 25 million senior secured credit facility.

Europe Medical Cannabis Industry Size, Share & Growth Outlook

According to IMARC Group, the Europe Medical Cannabis Industry reached USD 3,060.0 Million in 2025 and is projected to reach USD 13,161.29 Million by 2034, at a CAGR of 17.60% during 2026–2034. Growth is broad-based across species, derivatives, therapeutic applications, end users, delivery formats and countries, with the fastest expansion concentrated in Germany's import-fed pharmacy channel and the United Kingdom's private clinic network. The leading segments are:

• By Species: Indica accounts for the largest share of European demand, favoured for sleep, pain and spasticity indications where physicians prescribe most heavily. Sativa and hybrid varieties follow, with hybrid cultivars gaining ground as licensed producers standardise chemotypes and patients migrate between product SKUs on the basis of terpene profile rather than strain reputation.
• By Derivative: Cannabidiol (CBD)-led products hold over half of the market by derivative, reflecting the continent's preference for non-intoxicating, well-tolerated formulations in chronic pain, anxiety and paediatric epilepsy. Tetrahydrocannabinol (THC)-dominant products form the second group, prescribed mostly for neuropathic pain, spasticity and palliative care.
• By Application: Cancer is the largest single therapeutic application, spanning chemotherapy-induced nausea, appetite loss and cancer-related pain. Epilepsy, arthritis and migraine follow, with neurological and musculoskeletal indications expanding fastest as physician education improves.
• By End Use: The pharmaceutical industry generates the dominant share of volume, purchasing flower and extracts for processing into dispensable formulations, while research and development centres form the second group as clinical programmes in refractory pain and epilepsy mature.
• By Route of Administration: Oral solutions and capsules lead with a 37% share, the clearest evidence of the market's pharmaceutical character, followed by vaporizers, smoking and topicals as inhalation formats gain prescription share where rapid onset is clinically relevant.
• By Country: Germany leads on volume, patient base and import infrastructure, with the United Kingdom the fastest-growing second market. France, Italy and Spain form the next demand tier, while Portugal, Denmark and the Netherlands anchor cultivation and export capacity.

Recent News & Mega Announcements

Recent developments in the Europe Medical Cannabis Industry include significant announcements, investments and partnerships:

• In September 2026, Red White & Bloom Brands Inc. closed a strategic transaction with HEAL Botanicals Pharma, acquiring a 62.63% controlling interest in HEAL Europe Holdings Corp. for nominal consideration. The structure delivers an indirect 50.1% interest in Germany's Grünhorn Gruppe AG and an effective 61.3% of UK-based Zerenia Clinics Limited and Leva HEAL Limited, alongside a CAD 25 million senior secured credit facility of which CAD 18.7 million had been advanced at a fixed 12% rate maturing September 2029. The European platform filled roughly 290,000 medical cannabis prescriptions and dispensed or distributed more than 12 tonnes in the twelve months to July 2026.
• In September 2026, Aurora Cannabis Inc. confirmed that its acquisitions of UK pharmaceutical distributors Internode Pharma and HAP Pharma Limited are expected to support further market-share growth in Britain, alongside the accretive purchase of Safari Flower Company which adds EU-GMP cultivation capacity to its international supply network. The company reported USD 149 million in cash and no debt as of 30 June 2026 and reaffirmed sequential revenue and adjusted EBITDA growth guidance for its fiscal second quarter 2027.
• In April 2026, Curaleaf International completed the acquisition of the remaining 45% of Four 20 Pharma, a fully EU-GMP and GDP licensed German producer and distributor, having acquired an initial 55% stake in 2022. The full buyout consolidates a seed-to-patient chain stretching from cultivation in Portugal and Canada to licensed distribution in Germany, and the Four 20 brand has since been launched in the United Kingdom and Poland.
• In March 2026, Canify AG and MG Health Limited signed a Memorandum of Understanding to merge into a vertically integrated medical cannabis platform, combining EU-GMP cultivation and extraction at MG Health's facility in Lesotho with Canify's German pharmaceutical processing and pharmacy partnerships. The combined group targets commercial presence across more than seven countries including Germany, the United Kingdom, Australia and Poland, with planned expansion into Switzerland.
• In January 2026, BfArM published full-year 2025 import data confirming that Germany imported 201.1 tonnes of medical cannabis, nearly tripling 2024's total, sourced from more than 25 countries. Canada remained the dominant supplier at 93,006 kilograms (46%), followed by Portugal at 55,164 kilograms, Denmark at 9,319 kilograms and North Macedonia at 8,190 kilograms, with Malta, Czechia, Colombia, South Africa, Australia and the United Kingdom all recording sharp year-on-year increases.

Industry Trends Shaping 2026

Three trends are shaping the Europe Medical Cannabis Industry in 2026:

1. Germany's Import Scale-Up Reaches Industrial Volume

BfArM data show Germany imported 201.1 tonnes of medical cannabis in 2025, nearly tripling 2024's 72.9 tonnes, after the authority raised the national maximum quantity for medical and scientific purposes to approximately 192.5 tonnes in October 2025. Imports arrived from more than 25 countries, led by Canada at 93,006 kilograms (46%) and Portugal at 55,164 kilograms. BfArM's submission to the International Narcotics Control Board projects roughly ten tonnes of domestic German production in 2026, adding a second supply pillar to an import-dominated market.

2. The UK's Private Telemedicine Channel Goes Mainstream

Home Office data released under Freedom of Information in April 2026 put UK imports of dried cannabis flower for medicinal use at 30,062 kilograms in 2025, more than double the 14,992 kilograms recorded in 2024. Patient numbers are projected to pass 140,000 during 2026, up from roughly 100,000 a year earlier, while available cannabis-based medicines rose from 374 to 818 products. Growth is almost entirely private: more than 40 specialist clinics operate and fewer than a dozen telemedicine platforms issue around 80% of prescriptions, with average flower prices falling from £7.10 to £6.80 per gram.

3. EU-GMP Certification Becomes the Market-Access Currency

EU-GMP and Good Distribution Practice certification is now the entry ticket rather than a differentiator. Germany's domestic programme is supplied by three BfArM-tendered producers, while Portugal shipped 55,164 kilograms to Germany in 2025 and Denmark 9,319 kilograms, with licensed producers in North Macedonia, Malta, Colombia and South Africa expanding shipments. Because processing, stability testing and pharmacy release must occur inside the EU, operators are investing in German and Portuguese manufacturing capacity and in seed-to-sale compliance software rather than in bulk flower alone.

Geographic Hotspots

Germany is the gravitational centre of the Europe Medical Cannabis Industry and the world's largest legal import destination. BfArM recorded 201.1 tonnes of imports in 2025, nearly tripling the 72.9 tonnes of 2024, and raised the national maximum quantity for medical and scientific purposes to approximately 192.5 tonnes in October 2025 after the previous 122-tonne ceiling was exhausted. Demand is built on pharmacy dispensing under the Medical Cannabis Act, on statutory health insurance coverage for defined indications, and on a telemedicine-to-pharmacy fulfilment model that has made prescriptions routine rather than exceptional. Domestic cultivation under BfArM tender remains small by comparison producers are licensed for combined capacity in the low single-digit tonnes and BfArM's projection to the International Narcotics Control Board of roughly ten tonnes of German production for 2026 shows how far import dependence will persist.

The United Kingdom is the fastest-growing large market and the most purely private one. Home Office data released under Freedom of Information in April 2026 show dried flower imports of 30,062 kilograms in 2025 against 14,992 kilograms in 2024, and the patient base is projected to pass 140,000 during 2026. Because National Health Service prescribing remains rare, the economics rest on self-funded patients and specialist clinics: more than 40 private clinics operate, fewer than a dozen telemedicine platforms issue around 80% of prescriptions, and average flower prices have fallen from £7.10 to £6.80 per gram. That combination rapid volume growth, falling unit prices and near-total dependence on private payment makes the UK the most attractive acquisition market in Europe and also the most exposed to regulatory review.

Portugal and Denmark form the continent's cultivation and export base. Portugal shipped 55,164 kilograms to Germany in 2025, second only to Canada, and Denmark 9,319 kilograms, with both markets leveraging EU-GMP facilities, competitive energy costs and export licensing regimes operated by national medicines agencies. Spain, long the largest single source for the UK before Canadian bulk flower displaced it, still exported 4,794 kilograms to Germany in 2025, while Malta (4,858 kilograms), North Macedonia (8,190 kilograms) and Czechia (4,718 kilograms) illustrate how quickly secondary supply hubs can scale once EU-GMP certification is secured.

France, Italy, Spain and Poland are the next demand wave. France has built a complete permanent framework product authorisation by ANSM, therapeutic assessment and reimbursement evaluation by the HAS, and cultivation and traceability rules notified to the European Commission in March 2025 and has extended access for patients already in treatment beyond 31 March 2026. Italy relies on Ministry of Defence cultivation alongside licensed imports to relieve chronic domestic shortfalls, Spain is edging toward regulated dispensing, and Poland has become a genuine pharmacy market with a population of 38 million. Together these markets determine whether European growth stays concentrated in two countries or broadens into a genuine single market.

Competitive Landscape & Key Players' Strategies

Competitive activity is intensifying as leading players expand across the Europe Medical Cannabis Industry:

• Aurora Cannabis Inc.: Operates EU-GMP manufacturing in Canada and Germany and supplies European patients through brands including Pedanios, holding a share of German domestic cultivation capacity. Its strategy is now explicitly international and medical-only: the acquisitions of UK distributors Internode Pharma and HAP Pharma Limited add local commercial reach, while USD 149 million in cash and no debt as of 30 June 2026 fund further expansion.
• Tilray Brands, Inc.: One of the longest-established suppliers to German pharmacies and a holder of domestic cultivation capacity under the BfArM tender, using vertically integrated EU-GMP production and a broad product portfolio to defend share as imported flower commoditises and margin migrates to processing and distribution.
• Canopy Growth Corporation: Named among the leading competitors in IMARC's Europe analysis, it brings large-scale EU-GMP cultivation capacity and clinical research relationships into the European medical channel, positioning itself on pharmaceutical-grade consistency rather than price-led volume.
• Demecan GmbH: A German producer built specifically around the BfArM domestic cultivation licence, competing on short domestic supply chains, German-labelled product and proximity to pharmacy wholesalers an advantage as importers absorb freight, duty and quarantine costs on Canadian and Portuguese flower.
• Little Green Pharma: An Australian EU-GMP producer exporting into Germany and the UK, differentiating on standardised oil formulations and clinical documentation rather than raw flower, which insulates it from the sharpest price compression in dried flower and vape categories.
• Cannamedical Pharma GmbH: A German pharmaceutical wholesaler and importer supplying community pharmacies through licensed distribution, competing on the breadth of its imported brand portfolio, pharmacy relationships and telemedicine partnerships the infrastructure layer that now determines which products reach patients.
• Bedrocan International: The Dutch producer behind the Netherlands' official medicinal cannabis supply programme under the Office of Medicinal Cannabis, exporting standardised cultivars to multiple European markets and benefiting from one of the continent's longest track records in pharmaceutical-grade, government-supervised production.
• Panaxia Pharmaceutical Industries Ltd: Develops pharmaceutical-grade cannabinoid formulations and has pursued European market entry through licensed manufacturing and distribution partnerships, illustrating how formulation intellectual property, rather than cultivation acreage, increasingly attracts licensing and reimbursement interest.

Winning in this market increasingly depends on three capabilities: EU-GMP certified supply that can be released inside the EU, a licensed pharmacy and clinic distribution footprint in Germany or the United Kingdom, and the balance sheet to absorb price compression while national reimbursement frameworks are still maturing.

Policy & Regulatory Landscape

The Europe Medical Cannabis Industry operates within a supportive but nationally fragmented policy and regulatory framework:

• German Medical Cannabis Act (MedCanG): In force since 1 April 2024, it removed medical cannabis from the Narcotics Act (BtMG) and enabled ordinary physician prescriptions and pharmacy dispensing, the single change most responsible for the surge in German demand and imports.
• BfArM import quantity control: The Federal Institute for Drugs and Medical Devices administers Germany's annual maximum quantity for medical and scientific cannabis, reported under the 1961 Single Convention on Narcotic Drugs and the International Narcotics Control Board estimates system; the ceiling was raised to approximately 192.5 tonnes in October 2025 after the earlier 122-tonne limit was exhausted.
• EU-GMP (EudraLex Volume 4) and Good Distribution Practice: Together with Directive 2001/83/EC, these determine that only EU-GMP certified material may be released to European pharmacies, making certification, batch documentation and qualified-person release the binding operational requirements for every importer.
• UK Misuse of Drugs Regulations 2001: Cannabis-based products for medicinal use were moved to Schedule 2 in November 2018, permitting prescribing by doctors on the GMC specialist register; the absence of routine NHS commissioning is what pushed almost all UK prescribing into the private clinic sector.
• UK ACMD review and CQC oversight: The Advisory Council on the Misuse of Drugs is expected to conduct a formal review of the UK medical cannabis framework during 2026 or 2027, with telemedicine practice a focal point, while the Care Quality Commission has raised oversight and prescribing-consistency concerns at some private clinics.
• France's permanent framework: Draft regulatory texts were notified to the European Commission on 19 March 2025, cleared in June 2025 and validated by the Conseil d'État in summer 2025. ANSM will authorise cannabis-based medicines for renewable five-year periods and the HAS will assess therapeutic benefit to determine reimbursement, with patient access extended beyond 31 March 2026.
• Italy's state cultivation model: The Ministry of Defence cultivates cannabis domestically under a state monopoly for pharmacy dispensing, with government intent to expand cultivation and imported volumes to relieve structural shortages and reduce patient waiting times.
• Portugal's INFARMED licensing regime: Portugal's medicines regulator licenses cultivation, manufacturing and export, a framework that helped the country ship 55,164 kilograms to Germany in 2025 and become Europe's principal export platform.
• Netherlands Office of Medicinal Cannabis: The BMC within the Ministry of Health operates a supervised national production and distribution programme, one of the earliest templates for state-organised medical cannabis supply in Europe.
• Spain's AEMPS authorisation: The Spanish Agency for Medicines and Health Products authorises cultivation and export and maintains pharmacovigilance oversight, while parliamentary health committees continue to debate a formal medical dispensing framework.

Challenges & Risks

Key challenges and risks include:

• Import concentration and quota exposure: Canada supplied 93,006 kilograms 46% of German imports in 2025 and Canada and Portugal together represented roughly 68% of fourth-quarter volumes, so a single exporter's capacity decision or a quota dispute can move national supply; the mid-September 2025 pause in BfArM import approvals after the 122-tonne ceiling was exhausted shows how quickly policy mechanics disrupt trade.
• Price compression and oversupply: German imports fell 4.45% sequentially in the fourth quarter of 2025 after three quarters of double-digit growth, and UK flower prices slid from £7.10 to £6.80 per gram with vape prices down more than 20% over ten months to March 2026. Producers without in-house processing, release and pharmacy distribution absorb this pressure directly into gross margin.
• Reimbursement fragmentation: Germany funds defined indications through statutory insurance, the United Kingdom leaves almost all costs with self-paying patients, and France is still awaiting a HAS opinion on therapeutic benefit and reimbursement. Every additional market requires a separate evidence dossier and pricing negotiation, which is the largest single cost of scaling in Europe.
• Regulatory review and access tightening: The ACMD review of the UK framework in 2026 or 2027, CQC concerns about private clinic oversight, Poland's earlier telemedicine restrictions and repeated delays in publishing France's implementing decrees all demonstrate that prescription volumes can fall quickly when access rules change.
• Capital intensity, stigma and clinical capacity: EU-GMP facilities, stability testing, import permits and specialist distribution infrastructure require heavy, long-dated capital, while physician education and persistent stigma still limit prescribing outside a small group of cannabinoid-trained clinicians, constraining how fast patient numbers can realistically grow.
• Currency, freight and compliance cost volatility: Imported flower carries exposure to exchange-rate movement, cold-chain freight, quarantine and batch-release costs, and any tightening of EU-GMP interpretation raises the fixed cost base for every kilogram sold.

Forecast 2026–2034

IMARC Group projects the Europe Medical Cannabis Industry to expand from USD 3,060.0 Million in 2025 to USD 13,161.29 Million by 2034, at a CAGR of 17.60% (2026–2034).

That trajectory reflects a market in which the initial disruption of Germany's 2024 reclassification is giving way to a more mature phase in which compliance, distribution and clinic infrastructure decide competitive position rather than the simple ability to import flower. Germany will remain the volume and value anchor, with imports now running above 200 tonnes a year and domestic production projected by BfArM at roughly ten tonnes for 2026, while the United Kingdom supplies the second growth engine as its patient base moves toward 140,000 and beyond. France's transition to a permanent, reimbursed framework, Italy's expansion of state cultivation, and pharmacy-led growth in Poland and Czechia will broaden the market beyond two countries and reduce the concentration that currently defines it. EU-GMP processing capacity in Portugal, Denmark and Germany will keep supply competitive, price compression will continue in flower and vapes, and value will migrate toward oral solutions, capsules and standardised formulations where clinical evidence and reimbursement eligibility are strongest. The forecast period therefore delivers durable double-digit growth, but it belongs to operators that control processing, pharmacy release and patient access rather than bulk cultivation alone.

Opportunities for Stakeholders

• Manufacturers / Suppliers: Demand growth of 201.1 tonnes in Germany alone and 30,062 kilograms in the UK creates a sustained requirement for EU-GMP certified flower, extracts and standardised oils. Producers that hold EU-GMP and GDP certification, convert imported bulk flower into pharmacy-ready finished product inside the EU, and build oral solution and capsule capacity stand to capture the 55.2% of the market that sits in non-inhaled formats.
• Investors / Lenders: The market's expansion from USD 3,060.0 Million in 2025 to USD 13,161.29 Million by 2034, at a CAGR of 17.60% offers a regulation-anchored thesis. The most defensible assets are pharmacy and distribution platforms with recurring prescription volumes, licensed German importers and wholesalers, EU-GMP processing capacity in Portugal and Denmark, and UK clinic groups with proven patient acquisition economics as demonstrated by Red White & Bloom's secured lending structure alongside its equity control.
• Technology Providers: Demand is rising for seed-to-sale traceability and compliance software, e-prescription integration with German and UK clinic platforms, stability and batch-release management systems, and telemedicine infrastructure capable of handling prescription volumes that now exceed 290,000 at Germany's largest single platform. Providers that can audit a shipment from harvest to pharmacy shelf will find buyers among every licensed importer.
• Distributors / End Users: Pharmacy wholesalers, specialist clinical networks and telemedicine operators are the bottleneck and the value capture point in equal measure. Distributors that secure multi-year supply agreements across several origins Canada, Portugal, Denmark, North Macedonia and Malta reduce their exposure to quota and freight shocks, while clinics that offer structured dose titration and follow-up care defend patients against the price-led competition that is compressing margins.
• Clinic Operators / Health Systems: France's pending ANSM authorisation and HAS assessment route, Spain's movement toward regulated dispensing, and Poland's and Czechia's maturing pharmacy channels open first-mover positions in markets where patient access is still thin. Building physician training programmes and local clinical documentation now positions operators for reimbursement decisions as they are taken.

Conclusion: Germany and the UK Anchor Europe's Regulated Cannabis Build-Out

The Europe Medical Cannabis Industry, valued at USD 3,060.0 Million in 2025 and projected to reach USD 13,161.29 Million by 2034, at a CAGR of 17.60% (2026–2034), is being reshaped by three forces operating at once: Germany's Medical Cannabis Act of April 2024, which made cannabis an ordinary prescription medicine and lifted imports to 201.1 tonnes in 2025; the United Kingdom's private telemedicine channel, where imports reached 30,062 kilograms and patient numbers are heading past 140,000; and the slow, uneven construction of permanent frameworks in France, Italy, Spain and Poland that will determine how far growth spreads beyond two countries.

The obstacles are real concentrated supply from Canada and Portugal, quota mechanics that can pause trade, falling unit prices, fragmented reimbursement and pending regulatory reviews in Britain. Each is navigable by operators that certify EU-GMP supply, own processing and pharmacy distribution, and build clinical evidence alongside volume. For manufacturers, investors, technology providers and distributors, the coming decade offers a durable, regulation-driven growth platform whose value is increasingly captured near the patient rather than at the farm gate.